Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Benjamin L Maughan

Showing results (41-50 of 111) with videos related to

Pageof 12
Sort By:
The Oncologist|March 23, 2023
Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell CarcinomaHaoran Li, Kamal Kant Sahu, James Brundage, et al.
Heliyon|September 19, 2022
A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancersHaoran Li, Kamal Kant Sahu, Shruti Adidam Kumar, et al.
Journal of Kidney Cancer and VHL|August 5, 2024
Clinical, Genomic, and Transcriptomic Characteristics of Patients with Metastatic Renal Cell Carcinoma Who Developed Thromboembolic EventsGliceida Galarza Fortuna, Beverly Chigarira, Vinay Mathew Thomas, et al.
Clinical Genitourinary Cancer|January 22, 2013
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinomaBenjamin L Maughan, Neeraj Agarwal, Syed A Hussain, et al.
European Urology Focus|July 14, 2022
Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer SettingNicolas Sayegh, Nishita Tripathi, Roberto H Nussenzveig, et al.
Cancer Treatment and Research Communications|January 26, 2019
Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancerPrzemyslaw Twardowski, Jeffrey Y C Wong, Sumanta K Pal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2025
Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate CancerChadi Hage Chehade, Ryon P Graf, Zeynep Irem Ozay, et al.
Biomedicines|December 23, 2022
Detection of <i>BRCA1</i>, and <i>BRCA2</i> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World SettingTaylor Ryan McFarland, Vinay Mathew Thomas, Roberto Nussenzveig, et al.
Molecular Cancer Therapeutics|December 28, 2018
Germline Variant in <i>SLCO2B1</i> and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC)Andrew W Hahn, David M Gill, Austin Poole, et al.
Molecular Cancer Therapeutics|October 5, 2022
External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate CancerUmang Swami, Nicolas Sayegh, Yeonjung Jo, et al.
Pageof 12

Showing results (41-50 of 111) with videos related to

Sort By:
Pageof 12
The Oncologist|March 23, 2023
Phase I Trial of Combination Therapy With Avelumab and Cabozantinib in Patients With Newly Diagnosed Metastatic Clear Cell Renal Cell CarcinomaHaoran Li, Kamal Kant Sahu, James Brundage, et al.
Heliyon|September 19, 2022
A retrospective study to evaluate the efficacy and safety of SARS-CoV-2 vaccine in patients with advanced genitourinary cancersHaoran Li, Kamal Kant Sahu, Shruti Adidam Kumar, et al.
Journal of Kidney Cancer and VHL|August 5, 2024
Clinical, Genomic, and Transcriptomic Characteristics of Patients with Metastatic Renal Cell Carcinoma Who Developed Thromboembolic EventsGliceida Galarza Fortuna, Beverly Chigarira, Vinay Mathew Thomas, et al.
Clinical Genitourinary Cancer|January 22, 2013
Pooled analysis of phase II trials evaluating weekly or conventional cisplatin as first-line therapy for advanced urothelial carcinomaBenjamin L Maughan, Neeraj Agarwal, Syed A Hussain, et al.
European Urology Focus|July 14, 2022
Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer SettingNicolas Sayegh, Nishita Tripathi, Roberto H Nussenzveig, et al.
Cancer Treatment and Research Communications|January 26, 2019
Randomized phase II trial of sipuleucel-T immunotherapy preceded by sensitizing radiation therapy and sipuleucel-T alone in patients with metastatic castrate resistant prostate cancerPrzemyslaw Twardowski, Jeffrey Y C Wong, Sumanta K Pal, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 16, 2025
Association of Homologous Recombination Repair Alterations With Outcomes in Patients with Metastatic Hormone-Sensitive Prostate CancerChadi Hage Chehade, Ryon P Graf, Zeynep Irem Ozay, et al.
Biomedicines|December 23, 2022
Detection of <i>BRCA1</i>, and <i>BRCA2</i> Alterations in Matched Tumor Tissue and Circulating Cell-Free DNA in Patients with Prostate Cancer in a Real-World SettingTaylor Ryan McFarland, Vinay Mathew Thomas, Roberto Nussenzveig, et al.
Molecular Cancer Therapeutics|December 28, 2018
Germline Variant in <i>SLCO2B1</i> and Response to Abiraterone Acetate Plus Prednisone (AA) in New-onset Metastatic Castration-resistant Prostate Cancer (mCRPC)Andrew W Hahn, David M Gill, Austin Poole, et al.
Molecular Cancer Therapeutics|October 5, 2022
External Validation of Association of Baseline Circulating Tumor Cell Counts with Survival Outcomes in Men with Metastatic Castration-Sensitive Prostate CancerUmang Swami, Nicolas Sayegh, Yeonjung Jo, et al.
Pageof 12